InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: BioBS2012 post# 160502

Monday, 02/10/2014 1:01:45 PM

Monday, February 10, 2014 1:01:45 PM

Post# of 346071
maybe BMS does not want Peregrine to find conclusive clinical data that says "something bad" about Yervoy when its not combined with Bavituximab.... maybe BMS didn't reveal all info on their previous Yervoy data submitted to the FDA?

What is causing that optimal response? Its Bavituximab, which targets flipped-PS. Its certainly not Big Pharmas current downdreamers... >>> meant downstreamers!

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95570890&txt2find=yervoy|bavituximab


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News